Scalp Psoriasis: Clinical Considerations and Management

Clinical Overview

Scalp psoriasis is a chronic inflammatory dermatosis affecting the scalp and is among the most common sites of psoriasis involvement. This condition is characterized by erythematous plaques with silvery scale, often accompanied by pruritus and pain. Scalp psoriasis is challenging to treat due to the thick hair, cuticle barrier preventing topical drug penetration, and difficulty applying treatments without excessive staining or greasiness. Importantly, scalp psoriasis itself does not directly cause permanent hair loss (non-scarring), though severe inflammation or scratching may cause temporary telogen effluvium.

Epidemiology

Psoriasis affects approximately 2% of the global population, with scalp involvement occurring in 50-80% of all psoriasis patients. Scalp psoriasis can be the sole manifestation of disease (scalp-limited psoriasis) in approximately 5% of patients or coexist with body psoriasis in the majority. Age of onset of scalp psoriasis varies: some patients develop scalp involvement as their first manifestation while others develop it years into systemic disease. No sex predilection is documented. The disease often waxes and wanes, with stress, infection, medications, and seasonal changes triggering exacerbations. Scalp psoriasis shows high heritability; approximately 40% of patients have affected first-degree relatives.

Pathophysiology

Psoriasis is mediated by aberrant T-cell function and involves dysregulated production of pro-inflammatory cytokines including TNF-alpha, IL-17, and IL-23. In the scalp, this leads to keratinocyte proliferation, angiogenesis, and inflammatory cell infiltration, producing the characteristic erythema and scale. The scalp's unique physiology—dense hair follicles, sebaceous gland activity, increased humidity and moisture, and difficulty with hygiene—creates an environment conducive to psoriasis development and potentially more severe manifestations than on body skin. The condition is not contagious and does not damage hair follicles directly, distinguishing it from scarring alopecias.

Clinical Presentation

Scalp psoriasis manifests as erythematous (red) plaques covered with silvery or white scale on the scalp. The plaques may be confined to the scalp margins (hairline, postauricular areas) or involve the entire scalp. Scale accumulation can be substantial, creating visible flaking visible on shoulders and clothing. Pruritus is common, ranging from mild to severe; intense itching may drive scratching that further traumatizes skin and worsens inflammation. Some patients report scalp pain or tenderness, particularly when scale is extensive or in areas where scale tightly adheres to hair. Hair loss is typically telogenic (diffuse shedding) rather than permanent, occurring secondary to acute inflammation triggering synchronized entry of follicles into telogen phase. Compared to psoriasis on body skin, scalp psoriasis is often more resistant to treatment due to topical application challenges.

Diagnosis

Diagnosis is primarily clinical based on appearance of erythematous plaques with scale. Dermoscopy shows regular and narrow vessels at the dermal-epidermal junction ("regular vascular pattern") and regular distribution of scale. Scalp biopsy is rarely needed but shows regular acanthosis (epiderm al thickening), regular elongation of rete ridges, decreased granular layer, and neutrophilic microabscesses in the stratum corneum (Munro microabscesses). Importantly, diagnosis should consider differential diagnoses: seborrheic dermatitis (less distinct borders, more yellow-greasy scale), tinea capitis (unilateral, positive KOH preparation), lichen planopilaris (preserved hairline initially, more inflammatory), and atopic dermatitis (pruritus may be severe, often associated with other atopic conditions).

Treatment Algorithm

Treatment of scalp psoriasis is challenging due to the scalp's anatomical features limiting topical drug penetration. A stepwise approach from topical to systemic therapy is recommended.

First-line topical therapy includes potent topical corticosteroids (clobetasol propionate 0.05% solution or foam, betamethasone dipropionate 0.05% solution) applied directly to scaled plaques, typically twice daily. These are effective for most cases but continuous use >2 weeks carries risk of skin atrophy and systemic absorption. Scalp solutions provide better penetration than creams due to lack of hair barrier. Response rates are 60-70% with significant improvement at 2-4 weeks. Topical calcineurin inhibitors (tacrolimus 0.1% or pimecrolimus 1%) offer steroid-sparing alternatives for patients unable to tolerate long-term steroid use; however, these are less potent than corticosteroids. Response rates are 40-50%.

Keratolytic agents including salicylic acid (3-6% solution applied nightly) help soften and remove thick scale, improving penetration of other topical medications. Coal tar (1-3% solution) has long history of use with response rates of 50-60%, though messiness and potential carcinogenicity concerns limit use. Combination preparations (corticosteroid plus salicylic acid) improve efficacy compared to monotherapy.

Systemic therapy is indicated for severe or extensive scalp psoriasis unresponsive to topical treatment, or when psoriasis involves >10% of scalp or causes substantial functional impairment. Acitretin (oral retinoid, 0.5-1 mg/kg daily) achieves response in 60-70% of patients with psoriasis but is teratogenic and requires monthly monitoring. Methotrexate (15-25 mg weekly) is effective in 70-80% of moderate-to-severe psoriasis with good scalp penetration. Cyclosporine (3-5 mg/kg daily) shows rapid response (75-80%) but requires renal monitoring and carries long-term nephrotoxicity concerns.

Biologic therapies targeting TNF-alpha, IL-17, or IL-23 are highly effective: etanercept (TNF inhibitor) shows 60-70% response; ustekinumab (IL-23 inhibitor) shows 70-80% response; secukinumab (IL-17 inhibitor) shows 80-90% response. These are reserved for severe disease due to cost and infection risk from immune suppression.

Patient education regarding avoiding scratching, using gentle hair care, and minimizing heat styling helps reduce inflammation. Patients should use non-medicated shampoos as irritant shampoos may trigger flares.

Prognosis

Scalp psoriasis is a chronic disease with variable course: some patients achieve spontaneous remission or improvement over years, while others have persistent disease requiring ongoing therapy. Early intervention with topical corticosteroids controls symptoms in the majority (60-70%). Systemic therapy is highly effective for severe cases (70-90% response with biologics), but ongoing treatment is required as remission is uncommon once therapy is discontinued. Scalp psoriasis does not cause permanent baldness if treated appropriately, distinguishing it from scarring alopecias.

When to See a Dermatologist

Patients with scalp psoriasis unresponsive to over-the-counter treatments or experiencing significant pruritus, pain, or functional impairment should seek dermatology evaluation. Dermatologists can prescribe potent topical steroids and initiate systemic or biologic therapy if needed. Those with severe psoriasis affecting body skin should be referred to establish systemic treatment that addresses both scalp and body disease.

Frequently Asked Questions

Will scalp psoriasis cause permanent hair loss? No. Scalp psoriasis is non-scarring and does not permanently destroy follicles. Hair loss that occurs is temporary telogenic effluvium from acute inflammation, with regrowth expected once psoriasis is controlled.

Is scalp psoriasis contagious? No. Psoriasis is a genetic inflammatory condition, not infectious. Close contacts will not acquire psoriasis from an affected person.

How long does it take topical steroids to work on scalp psoriasis? Significant improvement typically occurs within 2-4 weeks of twice-daily potent topical corticosteroid use. Maximum benefit is usually achieved by 8-12 weeks.

Can I cure scalp psoriasis? Cure is not possible with current therapies, but excellent control is achievable in most patients. Discontinuing treatment typically results in disease recurrence within weeks to months.

References